- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05774119
Effect of Coffee Consumption on Appetite Traits in Overweight and Obesity
Effect of Coffee Consumption on Hunger, Satiety, and Appetite-regulating Hormones in Women With Overweight or Obesity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized crossover clinical trial to be realized in women between 20 and 40 years of age with overweight or obesity and apparently healthy who reside in the city of Guadalajara, Jalisco.
Their participation involves their attendance to 3 interventions, in the first one it is verified whether or not they meet the inclusion criteria, a clinical history is applied to take information on pathological history, clinical data, nutritional aspects, sociodemographic and lifestyle aspects and anthropometric measurements; then they are randomly assigned to the two types of interventions in the next two subsequent ones.
In the second and third interventions (with an interval of 7 days between them), participants will attend in the follicular phase of their menstrual cycle during the experiments to avoid variability in appetite.
They will arrive at the institute at 8 am after an overnight fast, consume a standard 400 kcal breakfast with a distribution of 55% carbohydrates, 30% lipids and 15% protein. along with 240 ml of coffee with 6 mg/caffeine/kg body weight or the same breakfast, but with 240 ml of water.
On an empty stomach and every 30 min during the 3 h following the consumption of breakfast with the beverage, the participants recorded their level of hunger, fullness, satiety, desire to eat and prospective consumption, desire to eat specific foods: sweet, salty, fatty, tasty, and sed through visual analog scales (VAS).
On an empty stomach, 30 minutes after consuming breakfast with the beverage and after 180 min, a blood sample will be taken from which serum will be obtained for glucose, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, triglycerides, ghrelin and cholecystokinin determinations.
In the first intervention, participants will be instructed to fill out a 24-hour reminder form to assess dietary intake, and will be asked to record all food and beverages consumed for 3 days prior to the two interventions. Participants will also be instructed to fill out a 24-hour post-breakfast reminder with or without coffee.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44340
- Universidad de Guadalajara
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women between 20 and 40 years old
- Body mass index between 25-40 kg/m2.
- Regular menstrual cycle of 23-32 days in the last 3 months.
- Moderate consumption of coffee (up to 4 cups per day)
- Having the habit of eating breakfast
- Availability of time in the morning
Exclusion Criteria:
- Use of any type of contraceptives in the last three months.
- Use of hypoglycemic, lipid-lowering, weight-loss, appetite altering and psychiatric medications.
- Diagnosis of diabetes mellitus, hypertension, cancer, polycystic ovary syndrome, hypothyroidism, hyperthyroidism, infectious disease, renal disease, dysgeusia, and gallbladder disease.
- Weight loss ≥5% of their weight in the last 6 months.
- Consumption of more than 20 g of alcohol per day.
- Smoking
- Pregnant or breastfeeding
- vegetarian or vegan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: breakfast with coffee
250 mL of water with 6 mg/caffeine/kg
|
breakfast with coffee with 6 mg/caffeine/kg body weight
|
|
Placebo Comparator: breakfast with water
250 mL of water
|
breakfast with 250 mL of water
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in dietary intake
Time Frame: Post intervention, the following 24 hours after finishing the intervention
|
Analysis of the 24 hour dietary intake recall consumed the rest of the day after the intervention.
Analyzed with the Nutritionist Pro TM Software.
|
Post intervention, the following 24 hours after finishing the intervention
|
|
Change in appetite feelings
Time Frame: Baseline and in the following 180 minutes postprandially, measured every 30 minutes.
|
Hunger, fullness, satiety, desire to eat and prospective consumption are assessed with the visual analog scales (VAS).
They are composed of 100 mm long lines, where at one end the term "None" or "Not at all" is placed and at the other end the term "Yes, a lot" or "As much as I have never felt".
The patient marks a point between these two extremes and quantification is done by measuring the distance from the left end of the line to the mark which is scored.
|
Baseline and in the following 180 minutes postprandially, measured every 30 minutes.
|
|
Change in desire for specific types of food
Time Frame: Baseline and in the following 180 minutes postprandially, measured every 30 minutes.
|
The desire to eat specific foods: sweet, salty, fatty, tasty and thirsty, was evaluated with visual analog scales, consisting of lines in which at one end is placed the term "Yes, very much" and at the other end the term "No, not at all".
The patient marks a point between these two extremes and quantification is done by measuring the distance from the left end of the line to the mark, to which a score is given.
|
Baseline and in the following 180 minutes postprandially, measured every 30 minutes.
|
|
Change in ghrelin concentration
Time Frame: Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
|
Ghrelin hormone measured by ELISA assay (Enzyme-Linked ImmunoSorbent Assay) according to the manufacturer's recommendations.
The kit is GHRL/Ghrelin ELISA Kit catalog number ELH-GHRL.
Ghrelin is measured in pg/mL.
|
Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
|
|
Change in cholecystokinin concentration
Time Frame: Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
|
Cholecystokinin measured by ELISA assay (Enzyme-Linked ImmunoSorbent Assay) according to the manufacturer's recommendations.
The kit is Human CCK Enzyme Immunoassay Kit catalog number EIA-CCK-1.
Cholecystokinin is measured in pg/mL.
|
Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in plasma glucose
Time Frame: Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
|
Peripheral blood samples were taken by a venous puncture after 12 h of fasting and at 120 min postprandial, and they were immediately centrifuged at 3500 rpm to obtain serum.
The serum was separated and stored at -80 ◦C for later use.
The concentration of glucose, was measured with a dry chemistry analyzer "Vitros 350 Chemistry" (Ortho-Clinical Diagnostics, Johnson & Johnson Services Inc., Rochester, NY, USA).
|
Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
|
|
Change in lipid profile: total cholesterol, triglycerides, high density lipoprotein, low-density lipoprotein, very low-density lipoprotein
Time Frame: Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
|
Peripheral blood samples were taken by a venous puncture after 12 h of fasting, 30 min and at 180 min postprandial, and they were immediately centrifuged at 3500 rpm to obtain serum.
The serum was separated and stored at -80 ◦C for later use.
The concentration of triglycerides, total cholesterol, and high-density lipoprotein cholesterol (HDL-c) cholesterol was measured with a dry chemistry analyzer Vitros 350 Chemistry (Ortho-Clinical Diagnostics, Johnson & Johnson Services Inc., Rochester, NY, USA).
Low-density lipoprotein cholesterol (LDL-c) was calculated with the Friedewald formula, except when triglycerides levels were higher than 400 mg/dL.
Very-low-density lipoprotein cholesterol (VLDL-c) was calculated as total cholesterol minus the sum of LDL-c + HDL-c.
|
Baseline, at 30 minutes postprandially, and at 180 minutes postprandially.
|
|
24 hour dietary intake recall pre-intervention
Time Frame: Baseline
|
Analysis of the 24 hour dietary intake recall consumed the day previous to the intervention.
Analyzed with the Nutritionist Pro TM Software.
|
Baseline
|
|
Physical activity
Time Frame: Baseline
|
It is evaluated with the International Physical Activity Questionnaire (IPAQ).
The questionnaire allows to obtain a quantitative calculation of the MET's (metabolic equivalents), which are a measure that expresses the energetic cost of physical activities.
A higher score indicates greater physical activity.
The minimum value is 3.3 MET´s /minute/week and there is no a maximum value.
|
Baseline
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CI-03421
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on breakfast with coffee
-
Federico II UniversityCompletedOverweight and ObesityItaly
-
MetroHealth Medical CenterCompleted
-
University of BrasiliaConselho Nacional de Desenvolvimento Científico e Tecnológico; MRC Human Nutrition...Completed
-
NYU Langone HealthCompletedBurnout, ProfessionalUnited States
-
Clinical Nutrition Research Centre, SingaporeUniversity of GuelphCompleted
-
Texas Tech UniversityPennington Biomedical Research Center; American Egg BoardCompletedDiabetes Mellitus, Type 2 | Insulin ResistanceUnited States
-
Maastricht University Medical CenterTop Institute Food and NutritionCompletedPostprandial IHL and IMCL DynamicsNetherlands
-
Duke UniversityCompletedHyperglycemia | Cardiovascular Disease | Diabetes, Type 2 | Diabetes, Type 1United States
-
University of AarhusAarhus University Hospital SkejbyCompletedRespiratory Aspiration of Gastric Content